01-671-998
Valproic Acid Monoclonal Antibody (VP13-607.1.D5), Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | 01-671-998-Each-of-1 | In Stock | ₹ 49,884.50 |
01-671-998 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 49,884.50
GST (18%): ₹ 8,979.21
Total Price: ₹ 58,863.71
Antigen
Valproic Acid
Classification
Monoclonal
Concentration
1.1 mg/mL
Formulation
PBS with no preservative; pH 7.4
Host Species
Mouse
Purification Method
Protein G
Regulatory Status
RUO
Target Species
Chemical
Product Type
Antibody
Isotype
IgG1
Applications
ELISA
Clone
VP13-607.1.D5
Conjugate
Unconjugated
Gene Alias
C8H16O2; Depakene; Depakine; Dipropylacetic acid
Immunogen
Valproic acid, conjugated to KLH.
Quantity
500 μg
Primary or Secondary
Primary
Content And Storage
-20° C, Avoid Freeze/Thaw Cycles
Form
Liquid
Target Molecule
Chemical
Related Products
Description
- MA1-10768 detects Valproic Acid
- MA1-10768 has been successfully used in ELISA applications
- The MA1-10768 immunogen is Valproic acid, conjugated to KLH
- Valproic acid, valproate sodium, and divalproex belong to the group of medicines called anticonvulsants
- They are used to control certain types of seizures in the treatment of epilepsy
- Also Valproic acid relieves histone deacetylases (HDACs) dependent transcriptional repression and causes hyperacetylation of histones in cultured cells and in vivo
- Valproic acid inhibits HDAC activity in vitro, most probably by binding to the catalytic center of HDACs
- Most importantly, valproic acid induces differentiation of carcinoma cells, transformed hematopoietic progenitor cells and leukemic blasts from acute myeloid leukemia patients
- More over, tumor growth and metastasis formation are significantly reduced in animal experiments
- Therefore, valproic acid might serve as an effective drug for cancer therapy.